航空航天医学杂志
航空航天醫學雜誌
항공항천의학잡지
Journal of Aerospace Medicine
2015年
9期
1059-1061
,共3页
替吉奥%奥沙利铂%胃癌%肝转移%不良反应
替吉奧%奧沙利鉑%胃癌%肝轉移%不良反應
체길오%오사리박%위암%간전이%불량반응
tegafur%oxaliplatin%gastric cancer%liver metastasis%adverse reaction
目的 分析替吉奥联合奥沙利铂一线治疗胃癌肝转移的临床治疗效果及不良反应.方法 选择2012年1月~2014年5月收治的46例晚期胃癌患者作为研究对象,根据不同治疗方法,把46例患者均分为对照组与观察组,每组各23例.对照组给予替吉奥、四氢叶酸和5-Fu治疗( FOLFOX方案),观察组给予替吉奥联合奥沙利铂( SOX方案)治疗,以21天作为1个治疗周期,经过2个周期治疗后,对比两组患者的临床治疗效果和不良反应.结果 观察组治疗总有效率65.2%,对照组治疗总有效率56.5%,两组临床治疗总有效率对比,无明显组间差异,无统计学意义(P>0.05);两组患者生存质量评分对比差异不明显,无统计学意义(P>0.05),两组总体不良反应轻,具有极好的耐受性,两组不良反应对比无明显差异,无统计学意义( P>0.05 ),观察组患者总生存期6.0月,对照组总生存期4.2月,两组对比,差异明显,具有统计学意义( P<0.05 ).结论 替吉奥联合奥沙铂利一线治疗胃癌肝转移的临床治疗效果较为理想,而且不良反应的发生率不高,改善患者生存质量明显,适合老年体弱患者应用,而且耐受性好,值得临床推广应用.
目的 分析替吉奧聯閤奧沙利鉑一線治療胃癌肝轉移的臨床治療效果及不良反應.方法 選擇2012年1月~2014年5月收治的46例晚期胃癌患者作為研究對象,根據不同治療方法,把46例患者均分為對照組與觀察組,每組各23例.對照組給予替吉奧、四氫葉痠和5-Fu治療( FOLFOX方案),觀察組給予替吉奧聯閤奧沙利鉑( SOX方案)治療,以21天作為1箇治療週期,經過2箇週期治療後,對比兩組患者的臨床治療效果和不良反應.結果 觀察組治療總有效率65.2%,對照組治療總有效率56.5%,兩組臨床治療總有效率對比,無明顯組間差異,無統計學意義(P>0.05);兩組患者生存質量評分對比差異不明顯,無統計學意義(P>0.05),兩組總體不良反應輕,具有極好的耐受性,兩組不良反應對比無明顯差異,無統計學意義( P>0.05 ),觀察組患者總生存期6.0月,對照組總生存期4.2月,兩組對比,差異明顯,具有統計學意義( P<0.05 ).結論 替吉奧聯閤奧沙鉑利一線治療胃癌肝轉移的臨床治療效果較為理想,而且不良反應的髮生率不高,改善患者生存質量明顯,適閤老年體弱患者應用,而且耐受性好,值得臨床推廣應用.
목적 분석체길오연합오사리박일선치료위암간전이적림상치료효과급불량반응.방법 선택2012년1월~2014년5월수치적46례만기위암환자작위연구대상,근거불동치료방법,파46례환자균분위대조조여관찰조,매조각23례.대조조급여체길오、사경협산화5-Fu치료( FOLFOX방안),관찰조급여체길오연합오사리박( SOX방안)치료,이21천작위1개치료주기,경과2개주기치료후,대비량조환자적림상치료효과화불량반응.결과 관찰조치료총유효솔65.2%,대조조치료총유효솔56.5%,량조림상치료총유효솔대비,무명현조간차이,무통계학의의(P>0.05);량조환자생존질량평분대비차이불명현,무통계학의의(P>0.05),량조총체불량반응경,구유겁호적내수성,량조불량반응대비무명현차이,무통계학의의( P>0.05 ),관찰조환자총생존기6.0월,대조조총생존기4.2월,량조대비,차이명현,구유통계학의의( P<0.05 ).결론 체길오연합오사박리일선치료위암간전이적림상치료효과교위이상,이차불량반응적발생솔불고,개선환자생존질량명현,괄합노년체약환자응용,이차내수성호,치득림상추엄응용.
Objective To analyze the Gio and oxaliplatin-line treatment of gastric cancer with liver metastases of clinical effect and adverse reactions.Methods 46 cases of patients with advanced gastric cancer from January 2012 to May 2014 in our hospital as the research object,depending on the treatment,the 46 patients were divided into a control group and the observation group,23 cases in each group.The control group received treatment for Gio,Gio observation group received oxaliplatin to 21d as a treatment cycle,after two cycles of treatment,clinical outcomes compared two groups of patients and adverse reactions.Results The total effective rate 65.2%,the total efficiency of the control group 56.5%,comparing two groups of clinical total efficiency,no significant between-group differences,no significant difference ( P>0.05);quality of life of the two groups of patients score was not significantly different contrast,no signif-icant (P>0.05),the two groups overall adverse reactions,with excellent tolerability,adverse comparison groups no significant difference was not statistically significant ( P>0.05),overall survival was observed in patients 6.0 months in the control group overall survival 4.2 months,comparing the two groups,the difference was significant,with statistical significance ( P<0.05 ).Conclusions Gio joint Osage platinum line treatment of gastric metastases benefit clinical effect is more ideal,but the incidence of adverse reactions is not high,significantly improve patients'quality of life for the elderly and frail patients use,and well tolerated,worthy of clinical application.
